25 September 2024
LYVA Labs invests £50,000 into health innovators Tectores
YVA Labs has completed a £50,000 investment into Tectores Ltd, a Wirral-based healthcare company. Tectores’ patented anti-friction technology, PelliTec®, is currently available in a pad, which is worn inside footwear to prevent blisters. The pad has been shown to reduce the...
18 September 2024
Monument Therapeutics announces grant of UK patent for neuroinflammation compound MT1980
MANCHESTER, England, Sept. 17, 2024 - Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the United Kingdom Intellectual Property Office ("IPO") has granted UK patent...
17 September 2024
First NCFB patient dosed in RESP-X Phase IIa study
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that the first patient has been dosed in a Phase IIa clinical trial for RESP-X, a new anti-virulence therapy to treat Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis...
10 September 2024
QV Bioelectronics delivers breakthrough pre-clinical safety and efficacy results for Electric Field Therapy in the treatment of Glioblastoma
• Safety of QV’s novel stimulation regimes demonstrated in large animal studies for up to three months of implantation. • Pre-clinical data demonstrates QV’s breakthrough proprietary stimulation methodology outperforms that of the industry leader in its effectiveness against...
6 September 2024
Respected pharma data science pioneer Dr Ben Sidders to spearhead Biorelate's next growth phase as Chief Scientific Officer
Dr Sidders brings two decades of deep data science experience, honed across multiple therapeutic areas at Pfizer and AstraZeneca. He will build on Biorelate's strong track record of leveraging advanced data science methods to extract critical knowledge from vast amounts of...
5 September 2024
QV Bioelectronics secures £343,000 from Innovate UK’s Cancer Therapeutics programme to develop a new treatment for childhood brain tumours
• The project will adapt QV Bioelectronics’ existing electric field therapy (EFT) technology to develop the world’s first fully implantable EFT device to treat Diffuse Midline Glioma (DMG). • DMG is a highly aggressive childhood brain cancer and ultra-orphan disease with a...
3 September 2024
Infex Therapeutics to present RESP-X Phase I data at ERS Congress
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that Phase I data from RESP-X, the Company’s first-in-class anti-virulence antibody, will be presented in an oral presentation by Colm Leonard, Chief Clinical Officer at Infex, at...
22 July 2024
Oxford BioTherapeutics named 'Best Tech SME of the Year' at Thames Valley Tech & Innovation Awards 2024
Oxford, UK and San Jose, California, 22 July 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, announces it has been recognized as the ‘Tech SME of the Year’ at the sixth...
20 June 2024
Wirral footcare manufacturer Tectores steps into India
Footcare product manufacturer Tectores has shifted its manufacturing from China to India as part of an expansion drive. Wirral-based Tectores produces PelliTec, a product that helps prevent blisters forming on feet. It was developed by friends Karl Ormond and Lenny Waters who...
20 May 2024
Infex Therapeutics strengthens its senior leadership team
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces it has appointed a new Director of Clinical Programmes, and promoted existing staff to strengthen its senior management team. Dr Kerry Nield has joined as Director of Clinical...